2346 related articles for article (PubMed ID: 32423788)
1. Natural and trained innate immunity against Mycobacterium tuberculosis.
Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
[TBL] [Abstract][Full Text] [Related]
2. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of M. tuberculosis Immune Evasion as Challenges to TB Vaccine Design.
Ernst JD
Cell Host Microbe; 2018 Jul; 24(1):34-42. PubMed ID: 30001523
[TBL] [Abstract][Full Text] [Related]
4. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
Front Immunol; 2018; 9():2371. PubMed ID: 30386336
[TBL] [Abstract][Full Text] [Related]
5. Mycobacterial Lipoprotein Z Triggers Efficient Innate and Adaptive Immunity for Protection Against
Chen Y; Xiao JN; Li Y; Xiao YJ; Xiong YQ; Liu Y; Wang SJ; Ji P; Zhao GP; Shen H; Lu SH; Fan XY; Wang Y
Front Immunol; 2018; 9():3190. PubMed ID: 30700988
[TBL] [Abstract][Full Text] [Related]
6. BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design.
Covián C; Fernández-Fierro A; Retamal-Díaz A; Díaz FE; Vasquez AE; Lay MK; Riedel CA; González PA; Bueno SM; Kalergis AM
Front Immunol; 2019; 10():2806. PubMed ID: 31849980
[TBL] [Abstract][Full Text] [Related]
7. Trained innate immunity and resistance to Mycobacterium tuberculosis infection.
Koeken VACM; Verrall AJ; Netea MG; Hill PC; van Crevel R
Clin Microbiol Infect; 2019 Dec; 25(12):1468-1472. PubMed ID: 30807849
[TBL] [Abstract][Full Text] [Related]
8. "The Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" - Meeting report.
Boggiano C; Eichelberg K; Ramachandra L; Shea J; Ramakrishnan L; Behar S; Ernst JD; Porcelli SA; Maeurer M; Kornfeld H
Vaccine; 2017 Jun; 35(27):3433-3440. PubMed ID: 28476627
[TBL] [Abstract][Full Text] [Related]
9. Is interferon-gamma the right marker for bacille Calmette-Guérin-induced immune protection? The missing link in our understanding of tuberculosis immunology.
Abebe F
Clin Exp Immunol; 2012 Sep; 169(3):213-9. PubMed ID: 22861360
[TBL] [Abstract][Full Text] [Related]
10. Mycobacterium tuberculosis infection and vaccine development.
Tang J; Yam WC; Chen Z
Tuberculosis (Edinb); 2016 May; 98():30-41. PubMed ID: 27156616
[TBL] [Abstract][Full Text] [Related]
11. A multiple T cell epitope comprising DNA vaccine boosts the protective efficacy of Bacillus Calmette-Guérin (BCG) against Mycobacterium tuberculosis.
Maurya SK; Aqdas M; Das DK; Singh S; Nadeem S; Kaur G; Agrewala JN
BMC Infect Dis; 2020 Sep; 20(1):677. PubMed ID: 32942991
[TBL] [Abstract][Full Text] [Related]
12. Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination.
Coppola M; Ottenhoff TH
Semin Immunol; 2018 Oct; 39():88-101. PubMed ID: 30327124
[TBL] [Abstract][Full Text] [Related]
13. BCG-mediated protection against M. tuberculosis is sustained post-malaria infection independent of parasite virulence.
Tangie E; Walters A; Hsu NJ; Fisher M; Magez S; Jacobs M; Keeton R
Immunology; 2022 Feb; 165(2):219-233. PubMed ID: 34775598
[TBL] [Abstract][Full Text] [Related]
14. Lung Epithelial Signaling Mediates Early Vaccine-Induced CD4
Das S; Marin ND; Esaulova E; Ahmed M; Swain A; Rosa BA; Mitreva M; Rangel-Moreno J; Netea MG; Barreiro LB; Divangahi M; Artyomov MN; Kaushal D; Khader SA
mBio; 2021 Aug; 12(4):e0146821. PubMed ID: 34253059
[TBL] [Abstract][Full Text] [Related]
15. Dietary pyridoxine controls efficacy of vitamin B6-auxotrophic tuberculosis vaccine bacillus Calmette-Guérin ΔureC::hly Δpdx1 in mice.
Gengenbacher M; Vogelzang A; Schuerer S; Lazar D; Kaiser P; Kaufmann SH
mBio; 2014 Jun; 5(3):e01262-14. PubMed ID: 24895310
[TBL] [Abstract][Full Text] [Related]
16. Nanocages engineered from Bacillus Calmette-Guerin facilitate protective Vγ2Vδ2 T cell immunity against Mycobacterium tuberculosis infection.
Pi J; Zhang Z; Yang E; Chen L; Zeng L; Chen Y; Wang R; Huang D; Fan S; Lin W; Shen H; Xu JF; Zeng G; Shen L
J Nanobiotechnology; 2022 Jan; 20(1):36. PubMed ID: 35033108
[TBL] [Abstract][Full Text] [Related]
17. Targeting innate immunity for tuberculosis vaccination.
Khader SA; Divangahi M; Hanekom W; Hill PC; Maeurer M; Makar KW; Mayer-Barber KD; Mhlanga MM; Nemes E; Schlesinger LS; van Crevel R; Vankayalapati R(; Xavier RJ; Netea MG;
J Clin Invest; 2019 Sep; 129(9):3482-3491. PubMed ID: 31478909
[TBL] [Abstract][Full Text] [Related]
18. Mucosal delivery of ESX-1-expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes.
Sathkumara HD; Muruganandah V; Cooper MM; Field MA; Alim MA; Brosch R; Ketheesan N; Govan B; Rush CM; Henning L; Kupz A
Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20848-20859. PubMed ID: 32778586
[TBL] [Abstract][Full Text] [Related]
19. A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis.
Rai PK; Chodisetti SB; Maurya SK; Nadeem S; Zeng W; Janmeja AK; Jackson DC; Agrewala JN
J Transl Med; 2018 Oct; 16(1):279. PubMed ID: 30305097
[TBL] [Abstract][Full Text] [Related]
20. Neonatal and infant immunity for tuberculosis vaccine development: importance of age-matched animal models.
Ramos L; Lunney JK; Gonzalez-Juarrero M
Dis Model Mech; 2020 Sep; 13(9):. PubMed ID: 32988990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
